TrialBlood advances2023

One-year safety and efficacy of mitapivat in sickle cell disease: follow-up results of a phase 2, open-label study.

Myrthe J van Dijk et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.